The prognostic significance of BRAF mutations in the natural course of melanoma is controversial. The aim of study was to assess the prognostic significance of BRAF V600E mutation in cutaneous melanoma patients. A total of 151 melanomas were included in the study. BRAF V600E mutation was detected using the Real Time PCR. BRAF V600E mutation rate was 51%. BRAF mutation rate was higher for young patients (61.4%) and upper limbs (63.2%), trunk (59.3%) and head&neck (59.2%) were the most frequently afflicted sites in BRAF-mutant patients, whereas lower limbs were mostly affected in BRAF-wild patients (77.8%). Likewise, acral melanomas rarely harbored BRAF mutation (17.1%). The disease-free survivals regarding the entire and stage III cohorts were longer in the BRAF-mutant group than in the BRAF-wild group (p = 0.006 and p = 0.004, respectively), whereas stage I-II patients had no survival differences between BRAF statuses (p = 0.2). Likewise, BRAF-mutant patients had better overall survival time compared to BRAF-wild patients in all stages (p = 0.01), in stage III (p = 0.01) and in stage IV patients (p = 0.001). However, no differences between BRAF statuses were observed in stage I-II melanomas (p = 0.3). In conclusion, BRAF V600E-mutant melanomas show favorable prognostic impact on both disease-free and overall survivals in all staged melanomas except local disease. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.
February 17, 2020
Rapamycin and dexamethasone during pregnancy prevents tuberous sclerosis complex associated cystic kidney disease.
June 4, 2020
Benzimidazole based fluorophores for the detection of amyloid fibrils with higher sensitivity than Thioflavin-T.
August 6, 2020
- ASCO – Lung CancerASCO.20 Virtual Scientific Program, held May 29 - 31, brought professionals from all over the world together to hear the brightest minds in oncology present state-of-the-art treatment modalities and new therapies.
- AACR-2020The American Association for Cancer Research is the world's oldest and largest professional association related to cancer research.
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.
- ASCO 2019The 2019 ASCO Annual Meeting, taking place May 31-June 4 in Chicago, will bring together more than 32,000 oncology professionals from across the globe. The theme of this year’s conference is Caring for Every Patient, Learning From Every Patient.